Effect of Coenzyme Q10 on the Outcome of Metabolic Dysfunction-Associated Fatty Liver Disease Patients
So far there has been no universal treatment for MAFLD since it has a complex etiology that involves ethnic, genetic, metabolic and environmental factors. However, therapeutic life changes including: diet, weight loss, and physical activity remain the cornerstone of treatment and is recommended by both American and European associations. Inflammatory biomarkers, such as tumor necrosis factor-alpha, and adipokines play key roles in the pathogenesis of MAFLD, hence, the anti-inflammatory and antioxidant effects of coenzyme Q10 especially at high doses that have not been tested are hypothesized to have a beneficial role in improving the systemic inflammation and biochemical variables. This study is conducted to test this hypothesis
∙ All study subjects and prior to consenting to the ICF, laboratory and imaging work-up will be evaluated for the presence of three out of five criteria for metabolic dysregulation in the context of metabolic -dysfunction associated fatty liver disease (MAFLD):
• Waist circumference (WC) ≥ 102/88 cm for men and women respectively.
• HDL cholesterol \<40 mg/dl in men and \<50 mg/dl in women or on specific drug therapy.
• Plasma Triglycerides ≥ 150 mg/dl or on specific drug therapy.
• Blood pressure ≥130 and/or ≥ 85 or on specific anti-hypertensive therapy.
• Fasting blood glucose ≥ 100 mg/dl or on specific anti hyperglycemic therapy
‣ Patients who agree to sign an informed consent
⁃ Adult patients \>18 years old.
⁃ Males and females
⁃ Willing to comply with procedures and follow up
⁃ Elevated serum transaminases (1-4 times the ULN)
⁃ Imaging evidence of fatty liver:
∙ pelviabdominal ultrasound and Fibro- CAP study